Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy - PubMed (original) (raw)
Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy
M I Gorziglia et al. J Virol. 1996 Jun.
Abstract
A novel recombinant adenovirus vector, Av3nBg, was constructed with deletions in adenovirus E1, E2a, and E3 regions and expressing a beta-galactosidase reporter gene. Av3nBg can be propagated at a high titer in a corresponding A549-derived cell line, AE1-2a, which contains the adenovirus E1 and E2a region genes inducibly expressed from separate glucocorticoid-responsive promoters. Av3nBg demonstrated gene transfer and expression comparable to that of Av1nBg, a first-generation adenovirus vector with deletions in E1 and E3. Several lines of evidence suggest that this vector is significantly more attenuated than E1 and E3 deletion vectors. Metabolic DNA labeling studies showed no detectable de novo vector DNA synthesis or accumulation, and metabolic protein labeling demonstrated no detectable de novo hexon protein synthesis for Av3nBg in naive A549 cells even at a multiplicity of infection of up to 3,000 PFU per cell. Additionally, naive A549 cells infected by Av3nBg did not accumulate infectious virions. In contrast, both Av1nBg and Av2Lu vectors showed DNA replication and hexon protein synthesis at multiplicities of infection of 500 PFU per cell. Av2Lu has a deletion in E1 and also carries a temperature-sensitive mutation in E2a. Thus, molecular characterization has demonstrated that the Av3nBg vector is improved with respect to the potential for vector DNA replication and hexon protein expression compared with both first-generation (Av1nBg) and second-generation (Av2Lu) adenoviral vectors. These observations may have important implications for potential use of adenovirus vectors in human gene therapy.
Similar articles
- Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.
Gorziglia MI, Lapcevich C, Roy S, Kang Q, Kadan M, Wu V, Pechan P, Kaleko M. Gorziglia MI, et al. J Virol. 1999 Jul;73(7):6048-55. doi: 10.1128/JVI.73.7.6048-6055.1999. J Virol. 1999. PMID: 10364357 Free PMC article. - Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.
Zhou H, O'Neal W, Morral N, Beaudet AL. Zhou H, et al. J Virol. 1996 Oct;70(10):7030-8. doi: 10.1128/JVI.70.10.7030-7038.1996. J Virol. 1996. PMID: 8794347 Free PMC article. - A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors.
Zhou H, Beaudet AL. Zhou H, et al. Virology. 2000 Sep 30;275(2):348-57. doi: 10.1006/viro.2000.0515. Virology. 2000. PMID: 10998335 - Adenovirus vectors deleted for genes essential for viral DNA replication.
Schaack J. Schaack J. Front Biosci. 2005 May 1;10:1146-55. doi: 10.2741/1607. Front Biosci. 2005. PMID: 15769613 Review. - Adenovirus-mediated in vivo gene transfer.
Brody SL, Crystal RG. Brody SL, et al. Ann N Y Acad Sci. 1994 May 31;716:90-101; discussion 101-3. doi: 10.1111/j.1749-6632.1994.tb21705.x. Ann N Y Acad Sci. 1994. PMID: 7517653 Review.
Cited by
- An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency.
Tan BT, Wu L, Berk AJ. Tan BT, et al. J Virol. 1999 Sep;73(9):7582-9. doi: 10.1128/JVI.73.9.7582-7589.1999. J Virol. 1999. PMID: 10438848 Free PMC article. - Identification of human butyrylcholinesterase organophosphate-resistant variants through a novel mammalian enzyme functional screen.
Zhang J, Chen S, Ralph EC, Dwyer M, Cashman JR. Zhang J, et al. J Pharmacol Exp Ther. 2012 Dec;343(3):673-82. doi: 10.1124/jpet.112.198499. Epub 2012 Sep 6. J Pharmacol Exp Ther. 2012. PMID: 22956723 Free PMC article. - Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes.
Qiao C, Li J, Skold A, Zhang X, Xiao X. Qiao C, et al. J Virol. 2002 Feb;76(4):1904-13. doi: 10.1128/jvi.76.4.1904-1913.2002. J Virol. 2002. PMID: 11799185 Free PMC article. - Recombinant Adeno-Associated Viral Vector-Mediated Gene Transfer of hTBX18 Generates Pacemaker Cells from Ventricular Cardiomyocytes.
Farraha M, Rao R, Igoor S, Le TYL, Barry MA, Davey C, Kok C, Chong JJH, Kizana E. Farraha M, et al. Int J Mol Sci. 2022 Aug 17;23(16):9230. doi: 10.3390/ijms23169230. Int J Mol Sci. 2022. PMID: 36012498 Free PMC article. - Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences.
Li Q, Guo Y, Wu WJ, Ou Q, Zhu X, Tan W, Yuan F, Chen N, Dawn B, Luo L, O'Brien E, Bolli R. Li Q, et al. Basic Res Cardiol. 2011 Nov;106(6):1355-66. doi: 10.1007/s00395-011-0207-7. Epub 2011 Jul 21. Basic Res Cardiol. 2011. PMID: 21779912 Free PMC article.
References
- J Virol. 1972 Sep;10(3):328-39 - PubMed
- Nat Genet. 1994 Jul;7(3):362-9 - PubMed
- J Gen Virol. 1977 Jul;36(1):59-74 - PubMed
- Proc Natl Acad Sci U S A. 1979 Aug;76(8):3665-9 - PubMed
- Cold Spring Harb Symp Quant Biol. 1980;44 Pt 1,:367-75 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous